Investor Presentaiton slide image

Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D Breyanzi provides transformational benefits to patients Before Breyanzi infusion 10 iber/mezi One month after Breyanzi infusion Follicular Lymphoma Patient from TRANSCEND-FL1 1. Images used with investigator permission from TRANSCEND-FL Ill Bristol Myers Squibbâ„¢ h Not for Product Promotional Use 78
View entire presentation